Botulinumtoxine: Wirksamkeit und Antigenität

Zusammenfassung

Der vorliegende Artikel geht auf Wirksamkeit und Antigenität der drei auf dem Markt verfügbaren Botulinumtoxine vom Typ A bzw. B (Dysport, Botox, Neurobloc) ein. Insbesondere der Darstellung des Wirkungsäquivalents wird besondere Aufmerksamkeit gewidmet (Botox : Dysport : Neurobloc = 1 : 3 : 30 - 100).

Abstract

This article focusses on potency and antigenic properties of the three botulinum toxin preparations available (Dysport, Botox, Neurobloc). In clinical practice, the equivalent dosages are of special importance (Botox : Dysport : Neurobloc = 1 : 3 : 30 - 100).

Key words

Botulinum toxin - A, B, antigenic property - Equivalent dosage

Literatur

• 1 Aoki R, Merlino G F, Spanoyannis A F, Wheeler L A. Preclinical Update on Botox (Botulinum Toxin Type A Purified Neurotoxin Complex) and Other Neurotoxin Preparations. Proc 4th European Botulinum toxin Symposium 1999: 2-3
• 2 Benecke R. Botulinum toxin for spasms and spasticity in the lower extremities. In: Jankovic J, Hallett M (eds) Therapy with botulinum toxin. New York; Marcel Dekker 1994: 557-565
• 3 Bigalke H, Shoer L. Clostridial neurotoxins.  Handbook Exp Pharm. 2000;  145 407-444
• 4 Bigalke H, Wohlfarth K, Irmer A, Dengler R. Botulinum A toxin: Dysport Improvement of biological availability.  Experimental Neurology. 2001;  168 162-170
• 5 Brin M F, Fahn S, Moskowitz C, Friedmann A. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm.  Mov Disord. 1987;  2 237-254
• 6 Bülbring E. Observations on the isolated phrenic nerve diaphragm preparation in the rat.  Br J Pharmacol. 1946;  1 38-61
• 7 Durif F. Clinical Bioequivalence of the Current Preparations of botulinum Toxin.  Eur Neurol. 1995;  2 17-19
• 8 Göschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H. Botulinum A Therapy: Neutralising and Nonneutralising Antibodies - Therapeutic Consequences.  Experimental Neurology. 1997;  147 96-102
• 9 Goodnough M C, Johnson E A. Stabilising of Botulinum Toxin Type A During Lyophilisation.  Appl Environ Microbiol. 1992;  58 3426-3428
• 10 Inoue K, Fujinaga Y, Watanabe T, Ohyama T, Takeshi K, Moriishi K, Nakajima H, Inoue K, Oguma K. Molecular composition of Clostridium botulinum type A progenitor toxins.  Infect Immun. 1996;  64 1589-1594
• 11 Hambleton P, Pickett A M. Potency Equivalence of Botulinum Toxin Preparations.  J R Soc Med. 1994;  87 719
• 12 Nuessgen Z, Roggenkaemper P. Comparison of two Botulinum-Toxin Preparations in the Treatment of Essential Blepharospasm.  Graefe's Arch Clin Exp Ophthalmol. 1997;  235 197-199
• 13 Poewe W, Schelosky I, Kleedorfer B. Treatment of spasmodic torticollis with local injections of botulinum toxin. One year follow-up in 37 patients.  J Neurol. 1992;  53 21-25
• 14 Rollnik J, Matzke M, Wohlfarth K, Dengler R, Bigalke H. Low dose treatment of cervical dystonia, Blepharospasm and facial hemispasm with albumin-dilutet botulinum toxin type A under EMG guidance.  Europ Neurol. 2000;  43 9-12
• 15 Schantz E, Johnson E A. Preparation and Characterisation of Botulinum Toxin Type A for Human Treatment. In: Jancovic J, Hallett M (eds) Therapy with Botulinum Toxin. New York, Basel, Hongkong; Marcel Dekker 1994: 41-49
• 16 Van den Bergh P, Francart J, Mourin S, Kollmann P, Laterre E C. Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin.  Muscle Nerve. 1995;  18 720-729
• 17 Wohlfarth K, Göschel H, Frevert J, Dengler R, Bigalke H. Botulinum A Toxins: Units Versus Units.  Naunyn-Schmiedeberg's Arch Pharmacol. 1997;  355 335-340
• 18 Zuber M, Sebald M, Bathien N, de Recondo J, Rondot P. Botulinum Antibodies in Dystonic Patients Treated with Type A Botulinum Toxin: Frequency and Significance.  Neurology. 1993;  43 1715-1718